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Abstract
Background: Chemical compounds affecting a bioactivity can usually be classified into several groups, each of
which shares a characteristic substructure. We call these substructures “basic active structures” or BASs. The
extraction of BASs is challenging when the database of compounds contains a variety of skeletons. Data mining
technology, associated with the work of chemists, has enabled the systematic elaboration of BASs.
Results: This paper presents a BAS knowledge base, BASiC, which currently covers 46 activities and is available on
the Internet. We use the dopamine agonists D1, D2, and Dauto as examples and illustrate the process of BAS
extraction. The resulting BASs were reasonably interpreted after proposing a few template structures.
Conclusions: The knowledge base is useful for drug design. Proposed BASs and their supporting structures in the
knowledge base will facilitate the development of new template structures for other activities, and will be useful in
the design of new lead compounds via reasonable interpretations of active structures.
Background
The bioactivity of chemical compounds can usually be
explained in terms of common structural features, and
the recognition of these features is the starting point in
drug design processes. For example, if a group of com-
pounds shares a large carbon skeleton, then recognition
of this aspect is relatively str a i g h t f o r w a r da tt h es t r u c -
tural formula and three-dimensional (3D) levels. How-
ever, structural aspects of drugs are very diverse, and no
catalog or database of characteristic substructures exists
that includes most known active compounds.
T h ec o n c e p to fab a s i ca c t i v es t r u c t u r e( B A S )i s
described herein and applied at the structural formula
level to express characteristic features shared by a group
of active compounds. This expression is similar to a
combination of the pharmacophore, or the component
indispensable to binding and biological activity, and the
scaffold, which consists of secondary components that
assist in ligand coordination. However, a BAS cannot
always be divided into these two components. Active
compounds are usually categorized into groups with a
BAS.
Many papers and reviews have been published that
propose relationships among characteristic substruc-
tures, structural modifications, and associated biological
activity. One typical approach is employed in the com-
mercial system LHASA [1], which compiles empirical
knowledge with QSAR results in toxicology and uses an
expert system framework to predict the toxic effects of a
new compound. Characteristic substructures of dopa-
mine agonists have been extracted based on purely
empirical considerations [2]. The present study was per-
formed to elaborate on the characteristic substructures
using dopamine agonists as an example.
Several reports have described automatic clustering
and classification of chemical substructures using var-
ious types of descriptor and fingerprint analyses to select
candidates for scaffold hopping and second-stage
screening of pharmaceutical compounds from vast
amounts of high-throughput screening (HTS) data [3].
Clustering, however, can result in mixing of different
structural classes within a cluster, or conversely, the
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© 2010 Okada et alappearance of many clusters containing only a single
compound. For example, Böcker attempted to improve
cluster purity first by the formation of a 2-means cluster
[4], followed by application of PCA scores [5] and the
introduction of MCS [6]. However, a mixture of com-
pounds with different structural features is essential to
the clustering technique as compounds are detected
from different structural classes to enable scaffold hop-
ping. Therefore, a user must always refer to a list of
supporting structures within a cluster to recognize the
structural characteristics of the cluster.
Another approach incorporates descriptors of prede-
fined graphs independent of the data set to be analyzed.
For example, data-driven clustering reported by Harper
[7] used reduced graph descriptors during the clustering
process and displayed those clusters that exhibited a
high activity ratio. Medina-Franco [8] used a similar
approach and isolated classes of active chemotypes. As
these methods retrieve database information through a
predefined series of scaffolds, the resulting cluster is
structurally homogeneous. However, the descriptors are
typically ring systems with side chains omitted. When
the side chain of the compound plays an important role
in its biological activity, the resulting cluster often con-
tains compounds of mixed activity and requires further
interpretation on the part of the chemist. Structurally
h o m o g e n e o u sc l u s t e r sa r ef a miliar to organic chemists,
and some commercial software packages employ this
approach [9].
The clustering applied in these approaches depends
essentially on fingerprints and descriptors, and does not
take into account the activity of the compound itself. A
conceptual clustering method based on chemical struc-
tures and incorporating activity ratios was proposed 20
years ago, but it was an experiment in artificial intelli-
gence with no real practical use [10].
A different approach to extract structural characteris-
tics from active compounds can be seen in CASE [11]
and MultiCASE [12] developed by Klopmann. These
methods use linear fragments and search through com-
binations of conditions for expression of activity, and
were used to extract common substructures in dopa-
mine agonists [13]. The same problem was analyzed to
a greater depth in the present study. Klopmann’sm e t h -
ods are now applied primarily for automated prediction
of toxicity, whereby common substructures are relatively
small compared to those found in pharmaceuticals.
Many computer scientists have focused their attention
on graph mining and have extended Klopmann’sw o r k
[14]. One of the research streams in this field uses
inductive logic programming, which in its first applica-
tion was used to recognize common structures of aro-
matic amines responsible for mutagenicity [15]. The
flexibility of this method is attractive, but the vast search
space represents a problem for graph mining. Recently,
the method was applied to scaffold hopping in 3D space
[16]. Another research stream that tackles SAR pro-
blems can be found in the work of DeRaedt. Molfea
constructed a lattice of SMILES fragments and suc-
ceeded in detecting meaningful fragments from a large
data set [17]. Later, a more sophisticated, rule-learning
algorithm was introduced in SMIREP [18]. The frame-
work for association rule mining was first extended to
graphs in AGM [19,20]. Recent work has included appli-
cation to large data sets [21]. All of these studies repre-
sent important progress in computer science with
attractive algorithms, and some valuable common struc-
tural features have been recognized from large data sets.
However, most of this work was done without strict eva-
luation by medicinal chemists. Therefore, mixtures of
trivial substructures often prevent further chemical
assessment.
Despite the large database of drugs available, no sys-
tematic method exists to extract BASs that are specific
for a desired activity. A collection of such BASs would
provide medicinal chemists with a means to generate a
general picture of their desired active compounds.
A successful method to extract BASs according to
their activities is described here. The method combines
data mining and the recognition of characteristic struc-
tures by medicinal chemists. Approximately 46 agonist/
antagonist activities have been characterized in terms of
their BAS components, as well as some repeated dose
toxicities for rats caused by chemical substances. To
date, the focus has been on biogenic amines, such as
dopamine, serotonin (5-HT), and adrenaline, and on
toxicities related to hemolytic anemia. The results have
been made available on the Internet as the BAS knowl-
edge base, Basic Active Structures in Chemicals (BASiC)
[22]. BAS extraction from dopamine D1 agonists is pro-
vided as an example, and the resulting BASs from D1,
D2, and Dauto agonists are described using template
structures. The results provide a more detailed under-
standing of active structures compared to previous stu-
dies [2,13].
Experimental
Overview of the analysis process
The MDL Drug Data Report (MDDR) database (version
2003.1) [23] was used as the data source, which contains
approximately 120,000 active compound records, includ-
ing those of dopamine agonists D1 (77 records), D2
(164 records), and Dauto (198 records). As the dopa-
mine molecule itself is an agonist of these three recep-
tors, these molecules were expected to share some
common structural features. The first step in the extrac-
tion process was to create a model with which to discri-
minate and characterize these three agonists. As some
Okada et al. Chemistry Central Journal 2010, 4:1
http://journal.chemistrycentral.com/content/4/1/1
Page 2 of 13of the compounds were expressed as salts, these were
converted into neutral molecules by omitting a counter
ion and an ammonium proton as well as adding a
hydrogen atom. Tautomers were converted to the most
common structure from the viewpoint of organic che-
mists. Duplicate structures were omitted, but optical iso-
mers were retained in the data set. The remaining 407
structures (D1, 74; D2, 162; Dauto, 194) were evaluated,
of which some affected multiple receptors.
The process of BAS extraction is described in steps (i)
through (iv) (see Additional file 1). (i) Linear fragments
were first extracted from the molecules and a table was
constructed in which each row represented a single
compound and the columns showed whether the corre-
sponding linear fragment exists in the compound. (ii)
The cascade model, a data mining method, was applied
to create characteristic rules for each activity. For conve-
nience, rules were arranged on a self-organizing map
(SOM) based on their coverage of compounds (see
Additional file 1). (iii) Each rule was then examined
using a structural refinement system. Examination of a
rule begins with optimization of the core characteristic
substructure to which the rule applies. The substructure
incorporates the surrounding atoms and bonds, and
increases the discriminating capability between active
and inactive compounds. The result is a larger, more
chemically meaningful substructure and a supporting
structures chart (SSC). (iv) Experienced chemists will
recognize BAS candidates in the SSC, as the structural
diversity and the number of compounds become rela-
tively limited. Finally, a BAS candidate is run through
the refinement system to confirm its ability to perform
the desired activity. Steps (iii) to (iv) are repeated until
the extracted BASs are those found in most of the active
compounds. Each step of BAS extraction is shown for
D1 agonists in the following subsections.
Generation and selection of linear fragments
Figure 1 shows a sample fragment [24] in a style similar
to the Simplified Molecular Input Line Entry System
(SMILES) notation. A fragment consists of two terminal
atoms and the shortest connecting path of atoms. An
atom symbol has qualifiers that show the number of
bonding neighbors and the presence of hydrogen atoms.
No notations are included to discriminate stereo- and
optical isomeric substructures. A carbonyl group is trea-
ted as a single, united atom. We generated all possible
fragments of length less than or equal to 10, but those
containing no heteroatoms were omitted. The number
of unique fragments generated was 4626 for the dopa-
mine agonist, and 660 fragments that appeared in 3%-
97% of all compounds were selected. Many cases
occurred in which two fragments were highly correlated.
We omitted one fragment if the correlation coefficient
of a pair was greater than 0.9 and if we could infer the
existence of a fragment from the presence of another
[25]. The final number of fragments was 335.
Rule generation by the cascade model
The cascade model is a mining method for generating
characteristic rules [26,27]. It detects links in the itemset
lattice where the activity ratio changes sharply in many
compounds. Figure 2 shows a typical example of a link
and its rule expression. Here, the problem contains four
explanatory variables–OH, CO, Me, COO–and a target
variable acid, which takes (y, n) values. The itemset at
the upper end of the link contains item [OH: y], and
another item, [CO: y], is added along the link. The two
small tables at the side of the nodes show the frequen-
cies of the items. We can see that a large distribution
change in acid (60/40 to 54/6) occurs with addition of
the [CO: y] item. The distribution of COO also changes
sharply. The cascade model searches for such links with
large distribution changes, and expresses them as rules.
T h et e x t b o xa tt h er i g h ti nF i g u r e2s h o w st h ed e r i v e d
rule. The added item [CO: y] appears as the main condi-
tion of the rule, while the items on the upper node ([OH:
y] in this case) are preconditions. The acid distributions
before and after application of the main condition are
s h o w ni nt h eTHEN clause as well as [COO: y] distribu-
tions denoted in a then clause at the bottom line.
The cascade model employs the between-groups sum of
squares (BSS) as a measure of rule strength to select these
characteristic rules. This BSSi sa l s ou s e di nt h er e f i n e -
ment process. Equation (1) is the sum of squares definition
for categorical data as given by Gini [28]. It is a simple
extension of the numerical sum of squares concept.
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The total sum of squares (TSS) can be decomposed
into the within-group sum of squares (WSS) and BSS
contributions, as shown in Equations (2)-(4), where n
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taking value i, respectively, and the superscript g is
attached to designate the group. The tree in Figure 3
shows an example of TSS decomposition. The top of
the tree represents 1000 cases consisting of 800 positives
and 200 negatives. The corresponding TSS value is 160,
as calculated by Equation (1). The cases are then divided
into two groups at the bottom according to some criter-
ion. The distributions in these groups are 760/40 on the
lower left and 40/160 on the lower right, with BSS
values of 18 and 72, respectively. The distribution in the
right group is inversely related to that at the top of the
tree. Hence, the right link has a higher BSS value
despite the smaller number of cases. We can also see
that the equality of Equation (4) holds for this sample.
We considered D2 and Dauto agonists as inactive,
when finding rules for D1 agonists. The application of
the cascade model yielded 21 rules (see Additional file 2
for details of rule selection). Figure 4 shows the stron-
gest rule that selects 60 D1 agonists from among 407
compounds.
The first line shows that this rule selects 60 of 407 com-
pounds, and the associated BSS value is 35.41. The sec-
ond line indicates that the main condition of this rule is
[O2H-c3:c3-O2H: y], the presence of a catechol with no
preconditions. The first THEN clause reveals that the
activity ratio rises from 18% in 407 compounds to 95%
in 60 compounds. The succeeding lines show variables
the distributions of which change sharply before and
after application of the main condition. For example, the
Figure 1 Explanation of a linear fragment and sample fragments. A sample fragment and its notations are described in the upper part of
the figure. The lower part of the figure shows three sample fragments and structural formulae, in which the fragment is shown in red.
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ratio decreases from 0.48 to 0.0, and the following then
clauses show that these fragments often appear with
catechol, suggesting the existence of a phenethylamine
meta and para to the OH group. In this way, one may
conceive of a dopamine structure by combining catechol
and phenethylamine substructures. However, the recog-
nition of a BAS has yet to be accomplished. For this, the
characteristic environment of the catechol substructure
must be considered.
Structural refinement
A structural refinement system was developed that
accounts for the surroundings of the substructure, while
maintaining the capability of the substructure to discri-
minate active compounds [29]. For the rule given in Fig-
ure 4, catechol was provided as an initial seed pattern,
and various other structures were generated by inserting
every type of bond atom pair into every position in the
seed. The generated structures were then entered as a
query to the database and a BSS value was computed.
Query structures with the highest BSS values were used
as the next seed pattern. The process was repeated until
every query structure resulted in a decrease in the BSS
value. The structures employed in this refinement
process are shown at the top of Figure 5, where an
increase in BSS values occurred only at step 3 in this
example.
The SSC displays active and inactive structures sepa-
rately at each step of the refinement. The lower section
of Figure 5 shows part of the SSC obtained from the
last refinement step. Components in red indicate the
common substructure obtained by refinement.
Designation of BASs and their knowledge base
The structure reached from a rule by the refinement sys-
tem sometimes gives a reasonable BAS. That is, the sup-
porting compounds of this BAS are those obtained by
substituent modifications from the BAS. However, a SSC
often contains a mixture of different skeletons from the
viewpoint of lead compound classification. The SSC
shown in Figure 5 is an example. In such cases, an experi-
enced medicinal chemist is able to recognize BAS candi-
dates in the SSC even though it contains a mixture of
compounds with differing structural features. A chemist
makes up a larger BAS candidate structure, and gives it to
the refinement system again to confirm whether the BAS
should be refined further. A BAS candidate query some-
times retrieves compounds with a low active/inactive ratio,
and the user must then modify the candidate structure.
Figure 2 Rule by the cascade model.
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Page 5 of 13Figure 3 A tree showing an example of TSS decomposition into WSS and BSS.
Figure 4 The strongest rule from the D1 agonist problem.
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on the user’s subjective judgment, and mechanizing this
selection process is difficult. In this study, chemists with
a great deal of experience in drug design for pharmaceu-
tical companies selected a BAS proactively if it could
inspire a chemist with the design of a new scaffold and
even if the number of supporting compounds is limited.
Five BASs were extracted from the SSC in Figure 5
and are presented in 57 active compounds. However, 17
active materials did not contain these BASs. The user
must then examine an additional rule that extends to
these 17 uncovered compounds. The extraction process
is then repeated until the resulting BAS list covers the
majority, if not all, of the active compounds.
T h ef i n a lk n o w l e d g eb a s et h e nc o n s i s t so fal i s to f
BASs, each of which consists of a structural formula, its
SMARTS expression, the number of covered active/inac-
tive compounds, and a SSC. Miscellaneous compounds
not covered by the BASs are also listed. The license of
the source database prohibits users from viewing the
SSC, but users can use compound ID lists to depict che-
mical structures if they have the right to access the
source database.
Results
BASs and their roles in D1 agonists
BASs extracted from D1 agonists are discussed in this
section. The introduction of a structural template is use-
ful in BAS interpretations. A template depicts a typical
structural pattern and serves as a standard for BAS
comparisons. A common template is shown in Figure 6
that applies to all D1, D2, and Dauto agonists. The
nitrogen atom at the center depicts the crucial amine
group, and j1 is an aromatic group substituted with an
OH group and separated by a certain distance (usually
2-3 atoms) from the amine. j2 is a lipophilic group that
includes aromatic functional groups. Differences in
Figure 5 An example of the structural refinement process and a part of the associated SSC.
Figure 6 General template for D1, D2 and Dauto agonists.
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Page 7 of 13structural arrangements among these components are
considered to be the discriminating factors determining
the three agonist activities.
The following two templates shown in Figure 7 are
proposed for D1 agonists, where j1 is a catechol and j2
is an aromatic ring. Figure 8 shows eight BASs extracted
from D1 agonists, which cover 70 of the 74 D1 active
compounds. Hereafter, the characteristic features in
these templates will be discussed as they relate to these
eight BASs.
The D1Ag-template1 is representative of BASs D1Ag-
A to -E. A typical BAS that expresses the features of this
template is D1Ag-A, which exhibits a rigid tetracyclic
system in which the steric arrangements of the catechol
OH, amine, and j2 groups are specified. Similarly,
D1Ag-B and -C have rigid carbon skeletons and are well
described by the template, although D1Ag-B does include
a few compounds without catechol groups and D1Ag-C
possesses rotational flexibility in the j2 arrangement.
D1Ag-D has more freedom with regard to the amine
location because the amine is not relegated to a ring in
most supporting compounds and the j2 group includes
nonaromatic moieties, such as cyclohexyl groups. Esters
of D1Ag-E have virtually the same structure as tem-
plate1, at least on the j1s i d e ,b e c a u s et h e yc a nb e
hydrolyzed to yield catechol. The amine groups of tem-
plate1 are primary or secondary in most compounds
except D1Ag-B. Although the arrangement of j2i s
coded less rigorously relative to that of j1, it is located
1-2 atoms from the amine group in most compounds.
D1Ag-template2 matches 18 compounds under D1Ag-
F, all of which also exhibit D2 agonist activity. In addi-
tion, they share two remarkable structural features: (i)
j2 is connected to the amine group viaa long flexible
chain, and (ii) another amine appears near j2. Two
compounds do not have catechol groups in template2,
but rather in the aromatic ring on the right side of
D1Ag-F, which can be interpreted via template1. In this
BAS, bending of the interconnecting six or eight atoms
may bring the two amine groups closer to each other
and the amine on j2, which then has the possibility of
becoming the active center.
BASs of D1Ag-G and -H cannot be explained by these
templates because they do not contain OH groups.
Indole nitrogen and oxo, oxime groups likely play the
role of the OH group. Three compounds of D1Ag-G
show D2 agonist activity. The availability of more data
in this category would enable a more detailed analysis.
Four compounds (see Additional file 3) that were not
covered by the eight BASs can be explained with D1Ag-
template1.
BASs and their roles in D2 agonists
There were 162 compounds that exhibited D2 agonist
activity, and their chemical structures showed markedly
richer variety than those of compounds exhibiting D1
activity. The four templates shown in Figure 9 are pro-
posed to represent the nine BASs shown in Figure 10,
where D2Ag-A, -B, and C- are subcategorized, and
D2Ag-A’ represents an additional BAS very similar to
D2Ag-A5.
D2Ag-template1 is representative of four subBASs:
D2Ag-A1 to D2Ag-A4. This template would be similar
to D1Ag-template1 if the X in -XR were substituted for
an oxygen atom. However, for this template, only one
OH at the meta position of phenethylamine is required,
as opposed to the two OH groups that comprised the
catechol in D1Ag-template1. The positions of the amine
and OH groups are fixed in these subBASs, and the OH
group is positioned to one side of the line connecting
the center of j1 to the amine, while the two OH groups
are located much closer to that line in D1Ag-template1.
The j2 group is often lacking in A2 and A4 com-
pounds, and it is located in the flexible environment of
A1 compounds, which includes a mostly aromatic lipo-
philic group. D2Ag-D, -E, -F, and -G are also repre-
sented by D2Ag-template1, where X in -XR is replaced
by X = N. However, the j2 group in the template is
absent in most supporting compounds of this category.
D2Ag-template2 is most representative of D2Ag-B,
with a characteristic -O-C-C- link between j1a n dt h e
amine group. The NH in the fused ring of j1 plays the
role of -XR in template1. Compounds with 1-3 atoms
between the amine and j2 are prevalent.
Figure 7 Templates for D1 agonists.
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Page 8 of 13Figure 8 Templates for D1 agonists. BASs extracted from D1 agonists. Broken lines indicate optional bond connections, and (m/n) denotes
the numbers of D1 active/inactive compounds covered by the BAS, respectively.
Figure 9 Templates for D2 agonists.
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large diversity of j1 moieties, as shown by subBASs C1
through C4. The relative positions of the amine group
and the benzene ring in j1 are similar to those in tem-
plate1. The -XR group in template1 corresponds to the
NH of the 5-membered rings of C3 and C4, but has no
counterpart in C1 or C2. j2 is connected to the amine
v i aal o n gf l e x i b l ec h a i n( a p p r o x i m a t e l y4a t o m si n
length), and it usually has a fused heterocyclic ring or
substituents with hydrogen-bonding capability. Nearly
half of the C1-supporting compounds are Dauto ago-
nists. The j2 group in many D2 agonists of this cate-
gory has a N-hetero ring connected to a flexible chain
at the N atom. If the j1-O-C-C-N chain in template2
adopts the same conformation as that in template3,
then these three templates exhibit approximately the
Figure 10 BASs extracted from D2 agonists. LPG refers to a lipophilic group.
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ring and the amine N atom.
The last template, D2Ag-template4, is representative
of BASs, D2Ag-A5 and D2Ag-A’. The former is identical
to D1Ag-F, and its supporting compounds show activity
with both D1 and D2. The j1 component of these BASs
is the same as that in template1, with j2 connected to
it via a long flexible chain that incorporates another
amine en route. Most of these compounds have a ben-
zene ring in the j2 component.
The amine groups at the active center in most D2
agonists are tertiary, but secondary amines prevail when
j1 is fused to a hetero 5-membered ring as shown in
D2Ag-A’ and B. At present, no adequate templates exist
that describe the remaining BASs: D2Ag-H with a 2-
aminothiazole ring, and D2Ag-I (identical to D1Ag-G)
without the aromatic ring. Four compounds are not cov-
ered by these BASs (see Additional file 3).
BASs and their roles in Dauto agonists
There were 194 compounds exhibiting Dauto agonist
activity. Evolutionarily, the Dauto receptor is closely
related to D2, and hence some of the five templates pro-
posed in Figure 11 resemble those of D2. Close inspec-
tion reveals that DAuAg-template1 has a similar
structure to D2Ag-template1 and 2, and that DAuAg-
template3 is almost identical to D2Ag-template3. Figure
12 shows the BASs extracted from Dauto agonists, some
of which are categorized as subBASs. All but seven of
the compounds with Dauto agonist activity contain one
or more of these BASs.
DAuAg-template1 can be associated with DAuAg-A
and -B. The j2 component typically consists of a -CH2-
Ar unit in DAuAg-A, and a -(CH2)3- A ro r- ( C H 2)3-O-
Ar unit in DAuAg-B. The large differences in linker
lengths suggest different docking modes. Four subBASs
of DAuAg-A contain a hydrophilic group in j1. D2Ag-
B, which is structurally similar to DAuAg-A, also
contains a hydrophilic group, but no corresponding
identical j1 structure is present in either of these BASs.
Another interesting observation is that both DAuAg-A
and B are specific to Dauto activity, although the super-
position of these structures results in D2Ag-B2, which
exhibits activity specific to D2.
The DAuAg-template2 is representative of DAuAg-C,
of which most associated compounds can be described
by subBASs C1 and C2. The j1 component of this tem-
plate consists of a 2-aminothiazole ring. This functional
group is also present in D2Ag-H, but the number of
associated compounds was not sufficient to warrant a
discussion of activity differences. The BAS of DAuAg-
C2 lacks a j2 component.
DAuAg-template3 is representative of DAuAg-D. The
j2 component of subBAS DAuAg-D1 is the 2-ami-
nothiazole ring that also appears in DAuAg-template2.
DAuAg-template3 is structurally similar to D2Ag-tem-
plate3, representing D2Ag-C. There are two likely rea-
sons for the observed activity differences: (i) the j1o f
D2Ag-C compounds often consists of a bicyclic system,
but is only present as such in one DAuAg-D compound,
and (ii) the distance to j2 is usually longer in DAuAg
than that in D2.
DAuAg-template4 is representative of DAuAg-E, and
most of the supporting compounds are expressed by
subBAS E1. This structure contains a unique thiophene
ring in j1 and a hydrophilic amido group between j1
and the amine. The formation of a hydrogen bond
between the oxygen atom in the methoxy group and the
NH group of the amide creates a pseudo 6-membered
ring that may act in place of j1 when combined with
the thiophene ring.
The last template, DAuAg-template5, is associated
with DAuAg-F, -G, and -H, all of which consist of a
rigid tricyclic system without a j2 component. Other
BASs, such as DAuAg-I and -J do not contain a tricyclic
j1 and the amine of DAuAg-I is not in a rigid
Figure 11 Templates for Dauto agonists.
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lack a j2 component and can therefore be categorized
under this template. The amine group at the active cen-
ter of the BAS is secondary in most compounds categor-
ized under template1 (with Ar-O-C-C-N), whereas it
appears as a tertiary amine in the other templates, with
the exception of a single compound. Seven compounds
are not covered by the BASs (see Additional file 3).
Conclusions
BASs were successfully extracted from chemical com-
pounds exhibiting a diverse array of structural features.
The key factor has been the incorporation of informa-
tion from the chemical environment surrounding the
BAS in addition to the empirical deduction of medicinal
chemists. That is, the discrimination of D1 agonists
from D2 and Dauto agonists can be achieved with the
catechol structure alone, and the refinement to aggre-
gate the phenethylamine group was useful. Designation
of a BAS was impossible without the empirical knowl-
edge of chemists.
T h eB A S i Ck n o w l e d g eb a s en o wc o n t a i n sB A S sf o ra
variety of activities related to dopamine, 5-HT, adrena-
line, adenosine, histamine, benzodiazepine, and
Figure 12 BASs extracted from Dauto agonists.
Okada et al. Chemistry Central Journal 2010, 4:1
http://journal.chemistrycentral.com/content/4/1/1
Page 12 of 13endothelin. BASs that exhibit various toxic and adverse
effects are also being extracted. Although BASiC does
not describe structural templates, the collection of
BASs, which includes supporting chemical structures,
would greatly aid in the design of new drugs and the
prediction of adverse effects.
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BAS: Basic Active Structure; SSC: Supporting Structures
Chart; BSS: Between-groups Sum of Squares.
Additional file 1: BAS extraction procedure. Figures of the flowchart
of analysis and SOM display are shown.
Additional file 2: Rule derivation process by the cascade model.
Detailed data in the rule set selection process is described.
Additional file 3: Miscellaneous compounds. The compound
structures not covered by BASs are shown for D1, D2 and Dauto
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